本帖最后由 老马 于 2012-1-13 21:20 编辑 8 w6 z. ~* \( |! X/ s |
Q. I2 x) G& B0 l
爱必妥和阿瓦斯丁的比较& d$ }( D1 q; d, d% i) O4 h: n
# m* {( ^1 \3 _$ r) o
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/& |. y# U" k/ M# S
! d9 r: h) f; E& d
- D5 e( }4 P, ehttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
' F% S! w5 E: `" K6 Y==================================================
# F' r2 d" k! x/ P2 WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)) M3 V7 O+ a# N9 W& s' Y9 n- @' ^
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 ^$ r- O( I1 Q+ F" vResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.! @8 \- F8 Z; F' g& Y% m
|